Khartis emerged from stealth with a $95 million total funding haul, including a $50 million Series B, to advance an oral IGF-1R inhibitor aimed at thyroid eye disease. The company tied its TED program to potential market differentiation versus infused therapies and said it plans a first clinical trial in early 2027. Boulevard Bio launched with $65 million from Deerfield to build a multi-specific antibody pipeline focused on B cell–driven autoimmune diseases. The startup positioned its approach as an immune-resetting strategy, echoing how immune biology continues to attract venture capital in the specialty autoimmunity segment.